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A B S T R A C T
Cardio-vascular diseases are the leading cause of morbidity and mortality. Ischemia is a state of oxygen
deprivation in tissues, whereas reperfusion is restoration of blood ﬂow in ischemic tissues. Myocardial
damage of tissue during reperfusion after ischemic insult is known as myocardial ischemia–reperfusion
(I/R) injury. It induces damage to cardiac muscle via increasing expression of oxygen, sodium and
calcium ions which are responsible in the activation of proteases and cell death. Heart renin angiotensin
system (RAS) plays an important role in the myocardial ischemia and reperfusion injury. Angiotensin (1–
7) is responsible for vasodilation and angiotensin II for vasoconstriction. Here-in we reviewed how
myocardial I/R injury sets in by up-regulation of angiotensin II that leads to increased infarct size, which
can be reduced by the use of ACE inhibitors, ACE2 activators and angiotensin II antagonist.
 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cardiovascular disease (CVD) or blood vessel disease, is the
leading cause of death worldwide.1 Ischaemic heart disease (IHD)
causes damage to heart muscle via deposition of cholesterol plaques
on the wall of coronary arteries and reducing the availability of
nutrients like glucose.2,3 Ischemia is deﬁned as an insufﬁcient supply
of the nutrient and oxygen to the cardiac muscle. During ischemia,
the level of glutathione, phosphocreatine and ATP are reduced while
hypoxanthine level gets elevated. Altered ion distribution, i.e.
increase in intracellular Ca2+/Na2+, cellular swelling, cytoskeleton
disorganization and acidosis of cells occur.4 During reperfusion
injury, blood ﬂow supply returns to the cardiac muscle that causes
release and activation of intracellular Ca2+ channel, formation of
cellular edema and damage to lipid membrane.5,6
The renin–angiotensin system (RAS) which is composed of
renin, angiotensin converting enzyme (ACE), angiotensin I and
angiotensin II, is localized in different areas of heart such as atria,
conduction system, valves, coronary vessels, ventricles, ﬁbroblasts
and myocytes.7,8 ACE 2 system is found in venous endothelial cells,* Corresponding author.
E-mail address: jkgupta81@rediffmail.com (J.K. Gupta).
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0019-4832/ 2016 Published by Elsevier B.V. on behalf of Cardiological Society of
creativecommons.org/licenses/by-nc-nd/4.0/).arterial smooth muscle cells, cardiac myocytes, myoﬁbroblasts,
thoracic aorta, carotid arteries and veins.9–11 Myocardial angio-
tensin receptors were discovered in 1980s. These receptors are the
supporter of local renin angiotensin system and intracardiac renin
angiotensin system. They play a very crucial role in cardioprotec-
tion. Major effector peptide in renin angiotensin system is
angiotensin II (vasoconstrictor), whose excess production increase
the blood pressure and leads to the damage of various organs like
brain, kidney and blood vessels.12 Angiotensin II antagonist and
angiotensin converting enzyme inhibitors (captopril and enalapril)
have cardioprotective effect by reducing the blood pressure and
infarct size.13,14
Cardiac angiotensinogen are glycoprotein of a2-globulin class,
synthesized in the cardiac muscle. Gene expression of angiotensino-
gen has been found in the mice and rats. Lower concentration of
angiotensinogen is found in the ventricles as compared to heart
atria. It has been reported that cardiac angiotensinogen mRNA level
in rat and mice liver is approximately 5% and 1%. Glucocorticoid
hormone treatment increases the production of hepatic angiotensi-
nogen in the rat heart. Dzau in 1987 observed that dietary sodium
raises the level of mRNA angiotensinogen in rat tissue, which could
be suppressed after ACE inhibitor treatment.15–17
Cardiac renin is a proteolytic enzyme which was discovered in
1898, by Robert Tigerstedt in Sweden. It has been documented that India. This is an open access article under the CC BY-NC-ND license (http://
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heart. An estimated 2% mRNA level is found in rat kidney and the
submaxillary gland of mice.18–20
Cardiac angiotensins are hormonal peptides, formed by the
proteolytic reaction of angiotensinogen and renin. Angiotensins
are of two types, angiotensin I and angiotensin II. Angiotensin I
have no biological role on heart renin angiotensin system. They are
precursor of angiotensin II and angiotensin III.21,22 Angiotensin II is
an effector hormone which plays a major role in heart renin
angiotensin system. It leads to hypertension by increasing
vasoconstriction and retention of ﬂuid and sodium in the body.23
Angiotensin II is also responsible for stimulation of inﬂammatory
mediators such as NAD(P)H oxidase, phospholipase A2 and JAK/
STAT pathway. De Leeuw in 1999 reported that angiotensin
converting enzymes treatment decreases angiotensin II level.24,25
Cardiac ACE are metallopeptides which are commonly distrib-
uted on epithelial and endothelial cells surface. ACE inhibitors have
been reported to exhibit protective effect on cardiovascular
disease.26 They are involved in the treatment for hypertension,
myocardial infarction and congestive heart failure (CHF) as they
inhibit angiotensin II formation.27 Angiotensin converting enzyme
2 is an exopeptidase with zinc membrane which help in the
conversion of angiotensin I and angiotensin II to angiotensin 1–9
and angiotensin 1–7. Angiotensin 1–7 is a vasodilator that further
converts into angiotensin 1–5 via ACE.28–30
2. Myocardial ischemia/reperfusion injury
Myocardial ischemia/reperfusion injury was ﬁrst discovered by
Jennings et al. in 1960. It develops when coronary blood supply to
myocardium is reduced. Restoration of blood ﬂow to ischemic
heart is necessary for maintaining heart physiology.31,32 The non-
lethal episodes of ischemia and reperfusion prior to global
myocardial ischemic insult have proved to reduce myocardial
injury, which is termed as preconditioning. Reperfusion can elicit a
cascade of adverse events that paradoxically causes injury of
tissue.33 During reperfusion after ischemic stress, hypoxanthine is
oxidized by xanthine oxidase which produces reactive oxygen
species (ROS).34 Ischemia followed by reperfusion is a stronger
cause of apoptosis than sustained ischemic insult. Ischemia due to
an anaerobic metabolism causes catabolism of adenine nucleotide
and leads to depletion of adenosine triphosphate (ATP).35 At the
time of reperfusion, xanthine oxidase metabolizes the hypoxan-
thine to xanthine and forms uric acid that leads to the formation of
huge amount of reactive oxygen species, i.e. superoxide anion
(O2), hydrogen peroxide (H2O2) and hydrogen radical (OH
).36During ische
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Fig. 1. Cellular myocardMyocardial IR injury usually causes inﬂammation on the cardiac
muscle and leads to hypoxia. This phenomena damages tissues by
activating leukocytes, cytokines, reactive oxygen species and
frequently develops during heart transplantation, infarction and
sepsis.37,38
3. Purpose of inﬂammatory cascade in myocardial ischemia/
reperfusion (I–R) injury
Ischemia is deﬁned as an insufﬁcient supply of the nutrient and
oxygen to the cardiac muscle. During ischemia, the level of
glutathione, phosphocreatine and adenosine triphosphate (ATP)
are reduced and hypoxanthine level gets elevated. Altered ion
distribution, i.e. increase in intracellular Ca2+/Na2+, cellular
swelling, cytoskeleton disorganization and acidosis of cells occur39
(Fig. 1).
Myocardial ischemia injury leads to the inhibition of oxidative
phosphorylation that decreases the level of adenosine diphosphate
(ADP) and elevates adenosine monophosphate (AMP). AMP further
forms adenosine that gets converted into inosine and hypoxan-
thine.40,41 Further hypoxanthine forms xanthine via xanthine
dehydrogenase and accounts for the activation of ROS.34 Inhibition
of Na+/K+ ATPase and formation of ionic homeostasis (increases of
Na+ and Ca+ ions) activates protease, i.e. calpains and phospho-
lipases which are responsible for direct apoptosis cell death.42,41 It
also release cytokine C in the cytoplasm then activates effectors
caspases and ruptures sarcolemmal membrane43 (Fig. 2).
During reperfusion injury, re-energization of mitochondria
generate reactive oxygen species.44,45 It is documented that cell
membrane damage during reperfusion is caused due to peroxida-
tion of lipid and oxidizing agents such as peroxynitrite and
hydroxyl radical.44,46 Both reactive oxygen species and restored pH
are responsible for the opening of mPTP during reperfusion injury.
Activation of mPTP accelerates the release of cyt C and caspases to
the ruptured sarcolemmal membrane that further leads to
apoptosis cell death47 (Fig. 3). During reperfusion followed after
ischemia, blood supply results in anaerobic metabolism, cardiac
muscles rupture, cytokines damage, micro-circulation clots and
accumulation of free radical in myocardium48 (Fig. 4).
4. Role of heart RAS in I/R injury and ischemic preconditioning
(IPC)
Renin angiotensin system plays an important role in myocardial
ischemic and reperfusion injury (I/R). Cardiac RAS system consist
of angiotensinogen, Ang I, Ang II, ACE, ACE 2, angiotensin 1–7,mia 
lls
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convert into angiotensin II (Ang II) via angiotensin converting
enzyme (ACE). Moreover, angiotensin I and angiotensin II
(vasoconstrictor) also convert into angiotensin 1–7 by neprilysin
endopeptide (NEP).12,49 I/R injury get upregulated by induction of
vasoconstrictors that leads to increased myocardial infarct size.50
Charan et al. in 2016 reported that atrial natriuretic peptide (ANP)
restores the attenuated cardioprotective effect of IPC in diabetic rat
heart51,52 (Fig. 5).
Singh et al., in 1999 investigated the cardioprotective role of
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Fig. 6. Role of heart renin angiotensin system in I/R injury and IPC: with the thas been shown to reduce LDH, CKMB and infarct size. Nunez et al.
reported that angiotensin-II induced preconditioning (APC) along
with ischemic preconditioning (IPC) exhibited cardioprotection by
affecting mitochondrial respiration and cardiac functions.53,54
Loot et al., in 2002 reported that angiotensin (1–7) attenuates
the development of heart failure after myocardial infarction in rat.
Trask et al., in 2007 observed that angiotensin (1–7) regulates
cardiac functions, blood pressure, cardiac hypertrophy, heart
failure and growth of cells. Angiotensin (1–7) has anti-proliferative
action on the vascular smooth muscles, cardiac muscles cells and
improves endothelial functions by releasing bradykinin and nitric
oxide.55,56
5. Cardiac RAS and the role of ACE inhibitor/ACE 2 activator and
angiotensin II antagonist
ACE inhibitors are vasodilators, used for the treatment of
hypertension, CHF and myocardial infarction. ACE inhibitors have
shown protective effect in 50% of patients with hypertension, and
have proved to reduce morbidity and mortality rates.57 They
inhibit angiotensin converting enzyme, which are responsible for
the formation of angiotensin II (a vasoconstrictor) and decrease the
myocardial infarct size. ACE inhibitor have shown to attenuate
myocardial (I/R) injury by reducing the level of angiotensin II and
increasing the level of angiotensin 1–7 (a vasodilator). They have
promising approach to restore the cardioprotective effect of
myocardial I/R injury58–60 (Fig. 6). Macedo et al., in 2016 reported
the cardioprotective effect of angiotensin converting enzyme
2 activator (diminazene aceturate) in cardiomyocytes hypertro-
phy.61 Qi et al., in 2013 reported that diminazene aceturate
attenuates ischemia induced cardiovascular diseases by enhancing
the activity of angiotensin converting enzyme 2. Diminazene
aceturate also attenuate left ventricular remodeling, post-myocar-
dial infarction and play a major role in the treatment of myocardial
infarction. ACE2 activates the circulating endothelial progenitor
cells in the blood which decreases the inﬂammatory cells and
increases the cardiac progenitor cells in the region of peri-infarct
cardiac muscles.62 It also enhances the function of heart andI) 
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Myocardial  in farct  size  get  decrease 
during the myocardial  I/R  injury and  IPC
or 
in 
reatment of ACE inhibitors, ACE2 activator and angiotensin II antagonist.
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ACE inhibitors (e.g. captopril) as well as ACE 2 activators (e.g.
diminazene aceturate) alone or in combination have shown to
attenuate the myocardial (I/R) injury by decreasing the level of
angiotensin II, increasing the level of angiotensin 1–7 and infarct
size reduction63 (Fig. 6). Angiotensin II antagonist drugs like
valsartan inhibits the angiotensin II and reduces infarct size.
Combined treatment of ACE inhibitors (e.g. captopril) and
angiotensin II antagonist (e.g. valsartan) has shown to attenuate
the myocardial (I/R) injury by decreasing the level of angiotensin
II64,65 (Fig. 6).
6. Conclusions
Myocardial damage of tissue during reperfusion after ischemia
insult is known as myocardial ischemia–reperfusion (I/R) injury.
Myocardial I/R injury increase the excessive expression of oxygen,
sodium and calcium ions which are responsible for activation of
proteases (e.g. calpaines and phospholipase) and lead to cardiac
cell death. In heart RAS, angiotensin-(1–7) is responsible for
vasodilation and angiotensin II is for vasoconstriction. In this
article, we have reported that I/R injury get upregulated by
angiotensin II which leads to increased infarct size. Above
evidences suggests that infarct size can be reduced by ACE
inhibitors, ACE2 activators and angiotensin II antagonist.
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